Management Concepts of Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) Among Chinese Physicians
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: No treatment is given.
- Who it may be relevant to
- Registry conditions: Liver Disease. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Attitudes, Perceptions, Clinical Practice, and Barriers in Diagnosis and Management of Patients With Metabolic Dysfunction-associated Steatotic Liver Disease: a Cross-sectional Survey on Physicians in China
Overview
This study is a cross-sectional survey-based study. The main goal of this study is to investigate the attitudes, perceptions, and clinical practice in assessing liver fibrosis following a metabolic dysfunction-associated steatotic liver disease (MASLD) diagnosis, and the management of MASLD patients among Chinese physicians in the departments of endocrinology / hepatology / infection / gastroenterology in Grade IIIA hospitals in provincial capitals or municipalities.
Interventions
- Other No treatment is given
This study is a cross-sectional survey-based study. The design is observational and descriptive. Collection of data will be performed via a quantitative online survey.
Primary outcome measures
- To investigate attitudes and perceptions concerning the reasons for further severity assessment (mainly refers to the assessment of liver fibrosis) following a MASLD diagnosis [Time frame: At the data capture (Day 1)]
- Methods used for diagnose liver fibrosis [Time frame: At the data capture (Day 1)]
- To find percentages of patients who undergo different liver fibrosis examination [Time frame: At the data capture (Day 1)]
- To find reasons for insufficient liver fibrosis assessment [Time frame: At the data capture (Day 1)]
- To investigate importance order of the reasons for insufficient liver fibrosis assessment [Time frame: At the data capture (Day 1)]
Eligibility criteria
Inclusion criteria
- Has provided informed consent.
- Registered clinical practice location in provincial capital or municipality.
- Physician with a license for clinical practice.
- Employed in the Department of Endocrinology, Hepatology, Infection or Gastroenterology.
- Hospital level: Grade IIIA hospital.
- Hold a professional title of associate chief physician or above, or senior attending physician (as an attending physician for more than or equal to (≥) 3 years).
- Conducts outpatient clinics for at least 1 half-days per week.
- The patient load of MASLD/MASH per month in the department should be:
- a. Endocrinology ≥20 patients per month
- b. Hepatology/Gastroenterology/ Infectious ≥30 patients per month
Exclusion criteria
-Participants will be excluded if they have unwillingness precluding adequate cooperation, fail to complete the questionnaire, or submit questionnaires verified as invalid.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Other
Study locations
China · 1 center
- Novo Nordisk Investigational site — Beijing
Identifiers
NCT: NCT07682363 · DAS-8853 · U1111-1336-6265